Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $25.97 in the last session, up 3.80% from day before closing price of $25.02. In other words, the price has increased by $3.80 from its previous closing price. On the day, 0.47 million shares were traded. KYMR stock price reached its highest trading level at $26.03 during the session, while it also had its lowest trading level at $24.74.
Ratios:
We take a closer look at KYMR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.53 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $52.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $60.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $55.BMO Capital Markets initiated its Market Perform rating on December 06, 2024, with a $55 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Chiniara Ellen sold 2,241 shares for $30.45 per share. The transaction valued at 68,239 led to the insider holds 80,085 shares of the business.
Chadwick Jeremy G sold 1,383 shares of KYMR for $42,113 on Mar 03 ’25. The Chief Operating Officer now owns 67,800 shares after completing the transaction at $30.45 per share. On Mar 03 ’25, another insider, Jacobs Bruce N., who serves as the Chief Financial Officer of the company, sold 7,035 shares for $30.45 each. As a result, the insider received 214,219 and left with 201,886 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 1686598272 and an Enterprise Value of 1285616256. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.83 while its Price-to-Book (P/B) ratio in mrq is 2.02. Its current Enterprise Value per Revenue stands at 27.312 whereas that against EBITDA is -5.127.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.20, which has changed by -0.23550189 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is -16.90%, while the 200-Day Moving Average is calculated to be -36.55%.
Shares Statistics:
According to the various share statistics, KYMR traded on average about 677.88K shares per day over the past 3-months and 1024460 shares per day over the past 10 days. A total of 64.89M shares are outstanding, with a floating share count of 53.88M. Insiders hold about 17.03% of the company’s shares, while institutions hold 95.05% stake in the company. Shares short for KYMR as of 1743379200 were 7990149 with a Short Ratio of 11.79, compared to 1740700800 on 7575085. Therefore, it implies a Short% of Shares Outstanding of 7990149 and a Short% of Float of 13.73.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Kymera Therapeutics Inc (KYMR) is currently in the spotlight, with 13.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.76 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$3.04 and -$4.72 for the fiscal current year, implying an average EPS of -$3.82. EPS for the following year is -$4.23, with 14.0 analysts recommending between -$2.68 and -$5.99.
Revenue Estimates
According to 17 analysts, the current quarter’s revenue is expected to be $10.73M. It ranges from a high estimate of $20M to a low estimate of $1.6M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $10.29MFor the next quarter, 17 analysts are estimating revenue of $12.38M. There is a high estimate of $30.1M for the next quarter, whereas the lowest estimate is $4M.
A total of 19 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $140M, while the lowest revenue estimate was $13.6M, resulting in an average revenue estimate of $60.1M. In the same quarter a year ago, actual revenue was $47.07M
